Log in to search using one of your social media accounts:

 

Management of Breast Cancer in Adjuvant Chemotherapy Settings in the Kanagawa Breast Oncology Group.
CONCLUSION: Given the varied therapeutic choices that we observed, clinical research is needed to provide appropriate, unified therapeutic strategies. PMID: 29228411 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 12, 2017 Category: Cancer & Oncology Authors: Terao M, Niikura N, Suzuki Y, Sengoku N, Arioka H, Ishikawa T, Tsugawa K, Tokuda Y Tags: Tokai J Exp Clin Med Source Type: research

Emerging innovative therapeutic approaches leveraging cyclin-dependent kinase inhibitors to treat advanced breast cancer.
PMID: 29226311 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 11, 2017 Category: Cancer & Oncology Authors: Cruz M, Reinert T, Cristofanilli M Tags: Clin Pharmacol Ther Source Type: research

Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis.
Abstract Breast cancer cells with stem cell properties are key contributors to metastatic disease, and there remains a need to better understand and target these cells in human cancers. Here, we identified rare stem-like cells in patients' tumors characterized by low levels of the proapoptotic molecule p53-upregulated modulator of apoptosis (PUMA) and showed that these cells play a critical role in tumor progression that is independent of clinical subtype. A signaling axis consisting of the integrin αvβ3, Src kinase, and the transcription factor Slug suppresses PUMA in these cells, promoting tumor stemn...
Source: Clinical Genitourinary Cancer - December 11, 2017 Category: Cancer & Oncology Authors: Sun Q, Lesperance J, Wettersten H, Luterstein E, DeRose YS, Welm A, Cheresh DA, Desgrosellier JS Tags: J Clin Invest Source Type: research

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.
PMID: 29227724 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 11, 2017 Category: Cancer & Oncology Authors: Blum JL, Robert N, Andersen J, Favret A, Ward P, Osborne C, Pippen J Tags: J Clin Oncol Source Type: research

Changes in Insurance Coverage and Stage at Diagnosis Among Nonelderly Patients With Cancer After the Affordable Care Act.
Conclusion Percent uninsured among nonelderly patients with newly diagnosed cancer declined substantially after the ACA, especially among low-income people who resided in Medicaid expansion states. A trend toward early-stage diagnosis for select cancers in expansion states also was found. These results reinforce the importance of policies directed at providing affordable coverage to low-income, vulnerable populations. PMID: 28885865 [PubMed - indexed for MEDLINE] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 9, 2017 Category: Cancer & Oncology Authors: Jemal A, Lin CC, Davidoff AJ, Han X Tags: J Clin Oncol Source Type: research

Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery.
Conclusion Blood pressure readings, blood draws, injections, and number or duration of flights were not significantly associated with increases in arm volume in this cohort. These findings may help to guide patient education about lymphedema risk reduction strategies for those who undergo bilateral breast cancer surgery. PMID: 28976793 [PubMed - indexed for MEDLINE] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 9, 2017 Category: Cancer & Oncology Authors: Asdourian MS, Swaroop MN, Sayegh HE, Brunelle CL, Mina AI, Zheng H, Skolny MN, Taghian AG Tags: J Clin Oncol Source Type: research

Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Conclusion ZA every 3 months was more CE in reducing the risks of SRE than monthly denosumab. This analysis was one of the first to incorporate the costs of generic ZA and one of the first independent CE analyses not sponsored by either Novartis or Amgen, the makers of ZA and denosumab, respectively. ZA every 3 months is the more CE option and more reasonable alternative to monthly denosumab. PMID: 29023215 [PubMed - indexed for MEDLINE] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 9, 2017 Category: Cancer & Oncology Authors: Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ Tags: J Clin Oncol Source Type: research

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
Abstract Purpose To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-modifying agents (BMAs) in metastatic breast cancer. This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain. Methods A joint ASCO-CCO Update Committee conducted targeted systematic literature reviews to identify relevant studies. Results The Update Committee reviewed three phase III noninferiority trials of dosing intervals, one systematic review and meta-analysis of studies of ...
Source: Clinical Genitourinary Cancer - December 9, 2017 Category: Cancer & Oncology Authors: Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B Tags: J Clin Oncol Source Type: research

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.
Abstract Purpose Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However, objective measures of cardiac function and health-related quality of life are lacking in long-term follow-up of patients who remain cancer free after completion of adjuvant treatment. Patients and Methods Patients in NSABP Protocol B-31 received anthracycline and taxane chemotherapy with or without trastuzumab for adjuvant treatment of node-positive, human epidermal growth factor receptor 2-positive early-stage breast cancer. A long-term follow-up assessment was undertaken for patients who were alive ...
Source: Clinical Genitourinary Cancer - December 9, 2017 Category: Cancer & Oncology Authors: Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N Tags: J Clin Oncol Source Type: research

PSAT1 is regulated by  ATF4 and enhances cell proliferation via the GSK3β/β-catenin/cyclin D1 signaling pathway in ER-negative breast cancer.
CONCLUSIONS: PSAT1, which is overexpressed in ER-negative breast cancers, is activated by ATF4 and promotes cell cycle progression via regulation of the GSK3β/β-catenin/cyclin D1 pathway. PMID: 29216929 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 8, 2017 Category: Cancer & Oncology Authors: Gao S, Ge A, Xu S, You Z, Ning S, Zhao Y, Pang D Tags: J Exp Clin Cancer Res Source Type: research

Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
Abstract Ductal carcinoma in situ (DCIS), invasive breast cancer (IBC) and lympho-vascular invasion (LVI) represent distinct stages in breast cancer progression with different clinical implications. Altered microRNA (miRNA) expression may play a role in mediating the progression of DCIS to IBC and LVI. The aim of this pilot study was to investigate whether differential miRNA expression could play a role in breast cancer progression. Cancer cells from DCIS, IBC and LVI were microdissected from formalin fixed paraffin embedded (FFPE) tissue of five breast cancer samples. MiRNA profiling of extracted RNA was performe...
Source: Clinical Genitourinary Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Soon PS, Provan PJ, Kim E, Pathmanathan N, Graham D, Clarke CL, Balleine RL Tags: Clin Exp Metastasis Source Type: research

The Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers without a First-Degree Relative with Breast Cancer.
The objective of this study was to estimate the lifetime risk of breast cancer in women with a BRCA1 or BRCA2 mutation with and without at least one first-degree relative with breast cancer. A total of 2835 women with a BRCA1 or BRCA2 mutation were followed. Age- and gene-specific breast cancer rates were calculated. The relative risks of breast cancer for subjects with a family history of breast cancer, compared to no family history were calculated. The mean age at baseline was 41.1 years, and they were followed for a mean of 6.0 years. The estimated penetrance of breast cancer to age 80 years was 60.8% for BRCA1 and 63.1...
Source: Clinical Genitourinary Cancer - December 5, 2017 Category: Cancer & Oncology Authors: Metcalfe KA, Lubinski J, Gronwald J, Huzarski T, McCuaig J, Lynch HT, Karlan B, Foulkes WD, Singer CF, Neuhausen SL, Senter L, Eisen A, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group Tags: Clin Genet Source Type: research

A comparison of tumour size measurements with palpation, ultrasound and mammography in male breast cancer: first results of the prospective register study.
CONCLUSIONS: Our data demonstrate that MG and US have similar accuracy with regard to tumour size estimation. US assessment showed the highest sensitivity in determining tumour size, followed by MG and CE. However, MG demonstrated a significant advantage for estimating the real tumour size for pT2 tumours compared to US or CE. PMID: 29204896 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 4, 2017 Category: Cancer & Oncology Authors: Streng M, Ignatov A, Reinisch M, Costa SD, Eggemann H Tags: J Cancer Res Clin Oncol Source Type: research

Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells.
CONCLUSIONS: Taken together, our results suggest that ACTN4 plays an important role in breast CSCs-related metastasis and is a novel therapeutic target of EA treatment. PMID: 29197410 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 2, 2017 Category: Cancer & Oncology Authors: Wang N, Wang Q, Tang H, Zhang F, Zheng Y, Wang S, Zhang J, Wang Z, Xie X Tags: J Exp Clin Cancer Res Source Type: research

Conventional US combined with acoustic radiation force impulse (ARFI) elastography for  prediction of triple-negative breast cancer and the risk of lymphatic metastasis.
Conventional US combined with acoustic radiation force impulse (ARFI) elastography for prediction of triple-negative breast cancer and the risk of lymphatic metastasis. Clin Hemorheol Microcirc. 2017;65(4):335-347 Authors: Pu H, Zhao LX, Yao MH, Xu G, Liu H, Xu HX, Wu R Abstract PURPOSE: To evaluate the combination of conventional ultrasound (US) and acoustic radiation force impulse (ARFI) elastography in predicting triple-negative breast cancer and the likelihood of lymphatic metastasis. MATERIALS AND METHODS: A total of 178 women presenting from May 2013 to September 2015 with pathological...
Source: Clinical Genitourinary Cancer - December 1, 2017 Category: Cancer & Oncology Authors: Pu H, Zhao LX, Yao MH, Xu G, Liu H, Xu HX, Wu R Tags: Clin Hemorheol Microcirc Source Type: research

Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting.
Abstract CONTEXT AND OBJECTIVES: The impact of complementary and integrative medicine (CIM) on adherence to chemotherapy regimens is unclear. We explored the effect of patient-tailored CIM treatments on the relative dose intensity (RDI) of chemotherapy among patients with breast and gynecological cancer. METHODS: Chemotherapy-treated patients with breast or gynecological cancer were referred by their oncology healthcare professional to a CIM treatment program. Adherence to integrative care (AIC) was defined as ≥4 CIM treatments, with ≤30 days between each treatment. Relative dose intensity (RDI) of...
Source: Clinical Genitourinary Cancer - November 29, 2017 Category: Cancer & Oncology Authors: Shalom-Sharabi I, Lavie O, Samuels N, Keinan-Boker L, Lev E, Ben-Arye E Tags: J Cancer Res Clin Oncol Source Type: research

Could parenchymal enhancement on contrast-enhanced spectral mammography (CESM) represent a new breast cancer risk factor? Correlation with known radiology risk factors.
Abstract AIM: To compare background parenchymal enhancement (BPE) on contrast-enhanced (CE) spectral mammography (CESM) with CE magnetic resonance imaging (MRI), and evaluate how these relate to hormonal status, mammographic breast density (MBD) and MRI fibroglandular tissue volume (FGTV). METHODS AND MATERIALS: Between June 2012 to October 2015, participants in a cancer staging study underwent full-field digital mammography (FFDM), CEMRI, and CESM. Two readers independently rated FGTV, MBD, and BPE using the Breast Imaging-Reporting and Data System (BI-RADS) criteria. Inter-reader reliability was estimated u...
Source: Clinical Genitourinary Cancer - November 29, 2017 Category: Cancer & Oncology Authors: Savaridas SL, Taylor DB, Gunawardana D, Phillips M Tags: Clin Radiol Source Type: research

Prognostic role of progesterone receptor expression in a population-based analysis.
Abstract PURPOSE: The role of progesterone (PR) expression in the management of breast cancer is controversial. The aim of this study is to evaluate the characteristics and prognosis of progesterone status among breast cancers patients in a population-based analysis. MATERIALS AND METHODS: Through the Tuscan Cancer Registry data on all the invasive breast cancer cases diagnosed during the period 2004-2005 in the provinces of Florence and Prato, central Italy, were retrieved. Histological reports were re-examined to obtain information on the percentage of positive tumor cells for estrogen (ER), progesterone (P...
Source: Clinical Genitourinary Cancer - November 29, 2017 Category: Cancer & Oncology Authors: Caldarella A, Barchielli A Tags: J Cancer Res Clin Oncol Source Type: research

Emerging Concepts in Gastric Neoplasia: Heritable Gastric Cancers and Polyposis Disorders.
This article reviews important histopathologic features and emerging concepts regarding gastric carcinogenesis in these syndromes. PMID: 29103540 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - November 8, 2017 Category: Cancer & Oncology Authors: van der Post RS, Carneiro F Tags: Surg Pathol Clin Source Type: research

Signatures derived from increase in SHARPIN gene copy number are associated with poor prognosis in patients with breast cancer.
We report three signatures produced from SHARPIN gene copy number increase (GCN-Increase) and their effects on patients with breast cancer (BC). In the Metabric dataset (n = 2059, cBioPortal), SHARPIN GCN-Increase occurs preferentially or mutual exclusively with mutations in TP53, PIK3CA, and CDH1. These genomic alterations constitute a signature (SigMut) that significantly correlates with reductions in overall survival (OS) in BC patients (n = 1980; p = 1.081e - 6). Additionally, SHARPIN GCN-Increase is associated with 4220 differentially expressed genes (DEGs). These DEGs are enric...
Source: Clinical Genitourinary Cancer - September 9, 2017 Category: Cancer & Oncology Authors: Ojo D, Seliman M, Tang D Tags: BBA Clin Source Type: research

Clinical value of CA 15-3 for detection of distant metastases in newly diagnosed breast cancer.
In conclusion, these facts confirm the independently predictive value of CA 15-3 before treatment on the existence of DM and the complementarity of the marker with the assessment of extension by imagery. PMID: 28751287 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - July 30, 2017 Category: Cancer & Oncology Authors: Gonssaud B, Goussot V, Berriolo-Riedinger A, Saïtta-Aribau E, Coutant C, Cochet A, Fumoleau P, Riedinger JM Tags: Ann Biol Clin (Paris) Source Type: research

Clinical value of CEA for detection of distant metastases in newly diagnosed breast cancer: comparison with CA 15-3.
In conclusion, these facts confirm the independently predictive value of CEA before treatment on the existence of DM and its complementarity with CA 15-3 during the assessment of extension by imagery. PMID: 28751288 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - July 30, 2017 Category: Cancer & Oncology Authors: Maccio G, Goussot V, Berriolo-Riedinger A, Riedinger JM Tags: Ann Biol Clin (Paris) Source Type: research

Cognitive Screening: Using the Clock-Drawing Test to Assess for Preexisting Deficits in Older Women Diagnosed With Breast Cancer 
.
Cognitive Screening: Using the Clock-Drawing Test to Assess for Preexisting Deficits in Older Women Diagnosed With Breast Cancer
. Clin J Oncol Nurs. 2017 Aug 01;21(4):489-498 Authors: Overcash J, Perry M Abstract BACKGROUND: Older women diagnosed with breast cancer may also have preexisting cognitive deficits.
. OBJECTIVES: The aim of the current study is to describe errors on the clock-drawing test (CDT), which is used to screen for preexisting cognitive deficits in older women diagnosed with breast cancer.
. METHODS: This descriptive study included a convenience sample of women aged...
Source: Clinical Genitourinary Cancer - July 25, 2017 Category: Cancer & Oncology Authors: Overcash J, Perry M Tags: Clin J Oncol Nurs Source Type: research

Survivorship Model of Care: Development and Implementation of a Nurse Practitioner-Led Intervention for Patients With Breast Cancer 
.
Survivorship Model of Care: Development and Implementation of a Nurse Practitioner-Led Intervention for Patients With Breast Cancer
. Clin J Oncol Nurs. 2017 Aug 01;21(4):E99-E105 Authors: Post KE, Moy B, Furlani C, Strand E, Flanagan J, Peppercorn JM Abstract BACKGROUND: Despite a call for action to improve survivorship care, no optimal model of care exists. 
. OBJECTIVES: To develop and evaluate the feasibility of a nurse practitioner (NP)-led model of care for survivorship visits after initial therapy. 
. METHODS: Patients received an NP-led survivorship bridge visit (NPSBV) followi...
Source: Clinical Genitourinary Cancer - July 25, 2017 Category: Cancer & Oncology Authors: Post KE, Moy B, Furlani C, Strand E, Flanagan J, Peppercorn JM Tags: Clin J Oncol Nurs Source Type: research

Prospective double blind randomized placebo-controlled clinical trial of the pectoral nerves (Pecs) block type II.
CONCLUSIONS: The Pecs block reduces postsurgical opioid consumption during the PACU stay time for patients undergoing breast surgery. PMID: 28625445 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - June 21, 2017 Category: Cancer & Oncology Authors: Versyck B, van Geffen GJ, Van Houwe P Tags: J Clin Anesth Source Type: research

Assessment of disease extent on contrast-enhanced MRI in breast cancer detected  at digital breast tomosynthesis versus digital mammography alone.
CONCLUSION: In both the DM- and DBT-screened populations with new cancer diagnoses, MRI is able to detect additional cancer; however, in those patients who have DBT screen-detected cancers the positive impact of preoperative MRI is diminished, particularly in those women with non-dense breasts. PMID: 28318506 [PubMed - indexed for MEDLINE] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - June 8, 2017 Category: Cancer & Oncology Authors: Chudgar AV, Conant EF, Weinstein SP, Keller BM, Synnestvedt M, Yamartino P, McDonald ES Tags: Clin Radiol Source Type: research

Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.
Abstract Increased human epidermal growth factor receptor 2 (HER2) expression is a hallmark of aggressive breast cancer. Imaging modalities have the potential to diagnose HER2-positive breast cancer and detect distant metastases. The heterogeneity of HER2 expression between primary and metastatic disease sites limits the value of tumor biopsies. Molecular imaging is a noninvasive tool to assess HER2-positive primary lesions and metastases. Radiolabeled antibodies, antibody fragments, and affibody molecules devise a reliable and quantitative method for detecting HER2-positive cancer using PET. HER2-targeted PET ima...
Source: Clinical Genitourinary Cancer - June 5, 2017 Category: Cancer & Oncology Authors: Henry KE, Ulaner GA, Lewis JS Tags: PET Clin Source Type: research

Theranostic Prospects of Gastrin-Releasing Peptide Receptor-Radioantagonists in Oncology.
Abstract Gastrin-releasing peptide receptors (GRPRs) represent attractive targets for cancer diagnosis and therapy owing to their overexpression in widespread human tumors. Bombesin (BBN) analogues coupled to suitable chelators for stable radiometal binding have been proposed for diagnostic imaging and radionuclide therapy (theranostics) of GRPR-positive tumors. Recently, interest has shifted from BBN-like receptor agonists to GRPR-radioantagonists, because radioantagonists do not induce adverse effects after injection to patients and display superior pharmacokinetic in vivo profiles. Thus, they seem more advantag...
Source: Clinical Genitourinary Cancer - June 5, 2017 Category: Cancer & Oncology Authors: Maina T, Nock BA, Kulkarni H, Singh A, Baum RP Tags: PET Clin Source Type: research

Urokinase Plasminogen Activator Receptor-PET with (68)Ga-NOTA-AE105: First Clinical Experience with a Novel PET Ligand.
Abstract Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using (68)Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with (68)Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker ...
Source: Clinical Genitourinary Cancer - June 5, 2017 Category: Cancer & Oncology Authors: Skovgaard D, Persson M, Kjaer A Tags: PET Clin Source Type: research

Risk-based Breast Cancer Screening: Implications of Breast Density.
This article reviews the current evidence regarding the impact of breast density relative to other known risk factors, the evidence regarding supplemental screening for women with dense breasts, supplemental screening options, and recommendations for physicians having shared decision-making discussions with women who have dense breasts. PMID: 28577623 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - June 5, 2017 Category: Cancer & Oncology Authors: Lee CI, Chen LE, Elmore JG Tags: Med Clin North Am Source Type: research

Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites.
Abstract BACKGROUND: The analysis of relationships of BRCA alterations with cancer at sites other than breast/ovary may provide innovative information concerning BRCA pathogenic role and support additional clinical decisions. Aim of this study is to compare presence of cancers in other sites in members of hereditary (H) and not-hereditary (nH) branches of families of patients eligible to BRCA test. METHODS: We retrospectively analyzed the incidence of cancer in other sites in members of 136 families eligible for hereditary breast/ovarian cancer genetic counseling at Centro Studi Tumori Eredo-familiari of our ...
Source: Clinical Genitourinary Cancer - June 1, 2017 Category: Cancer & Oncology Authors: Digennaro M, Sambiasi D, Tommasi S, Pilato B, Diotaiuti S, Kardhashi A, Trojano G, Tufaro A, Paradiso AV Tags: Hered Cancer Clin Pract Source Type: research

Global Health Initiatives of the International Oncology Community.
This article discusses some of these initiatives. PMID: 28561641 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - June 1, 2017 Category: Cancer & Oncology Authors: Al-Sukhun S, de Lima Lopes G, Gospodarowicz M, Ginsburg O, Yu PP Tags: Am Soc Clin Oncol Educ Book Source Type: research

Pancreatic Adenocarcinoma: Improving Prevention and Survivorship.
Abstract Pancreatic cancer is a growing problem in oncology, given slowly rising incidence and continued suboptimal outcomes. A concerted effort to reverse this tide will require prevention, early diagnosis, and improved systemic therapy for curable disease. We focus on these aspects in detail in this study. Hereditary pancreatic cancer is an underappreciated area. With the growing use of genomics (both somatic and germline) in cancer care, there is increasing recognition of hereditary pancreatic cancer cases: around 10% of all pancreatic cancer may be related to familial syndromes, such as familial atypical multi...
Source: Clinical Genitourinary Cancer - June 1, 2017 Category: Cancer & Oncology Authors: Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S Tags: Am Soc Clin Oncol Educ Book Source Type: research

Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management.
Abstract Breast cancer is the second most common primary tumor associated with central nervous system (CNS) metastases. Patients with metastatic HER2-positive or triple-negative (estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, HER2-negative) breast cancer are at the highest risk of developing parenchymal brain metastases. Leptomeningeal disease is less frequent but is distributed across breast cancer subtypes, including lobular breast cancer. Initial treatment strategies can include surgery, radiation, intravenous or intrathecal chemotherapy, and/or targeted approaches. In this article, we re...
Source: Clinical Genitourinary Cancer - June 1, 2017 Category: Cancer & Oncology Authors: Lin NU, Gaspar LE, Soffietti R Tags: Am Soc Clin Oncol Educ Book Source Type: research

Optimizing Breast Cancer Adjuvant Radiation and Integration of Breast and Reconstructive Surgery.
Abstract Postmastectomy radiotherapy (PMRT) reduces the risk of locoregional and distant recurrence and improves overall survival in women with lymph node-positive breast cancer. Because of stage migration and improvements in systemic therapy and other aspects of breast cancer care, the absolute benefit of PMRT and regional nodal irradiation may be small in some favorable subsets of patients with very low nodal burden, and newer consensus guidelines do not mandate PMRT in all node-positive cases. The use and need for PMRT may considerably complicate breast reconstruction after mastectomy and therefore mandates mul...
Source: Clinical Genitourinary Cancer - June 1, 2017 Category: Cancer & Oncology Authors: Kuerer HM, Cordeiro PG, Mutter RW Tags: Am Soc Clin Oncol Educ Book Source Type: research

Lifestyle Interventions to Improve Cardiorespiratory Fitness and Reduce Breast Cancer Recurrence.
Abstract As patients are living longer after a cancer diagnosis, survivorship is becoming increasingly important in cancer care. The sequelae of multimodality therapies include weight gain and decreased cardiorespiratory fitness, which increase cardiovascular risk. Evidence suggests that physical activity reduces the risk of breast cancer recurrence and death. Avoidance of weight gain after therapy also improves outcomes after a diagnosis of breast cancer. Prospective randomized trials must be performed to determine the benefits of specific physical activity and dietary habits for survivors of breast cancer. This ...
Source: Clinical Genitourinary Cancer - June 1, 2017 Category: Cancer & Oncology Authors: Haykowsky MJ, Scott JM, Hudson K, Denduluri N Tags: Am Soc Clin Oncol Educ Book Source Type: research

Standard and Genomic Tools for Decision Support in Breast Cancer Treatment.
Abstract Over the past few decades, comprehensive characterization of the cancer genome has elucidated pathways that drive cancer and mechanisms of resistance to therapy and provided important insights for development of new therapies. These advances have resulted in the development of prognostic and predictive tools for use in clinical settings, which can assist clinicians and patients in making informed decisions about the benefits of established therapies. In early-stage breast cancer, multiparameter genomic assays are now available for decision making about the duration of adjuvant endocrine therapy and the us...
Source: Clinical Genitourinary Cancer - June 1, 2017 Category: Cancer & Oncology Authors: Henry NL, Bedard PL, DeMichele A Tags: Am Soc Clin Oncol Educ Book Source Type: research

Optimal Management of Early and Advanced HER2 Breast Cancer.
This article also reviews how to approach patients with advanced HER2-positive disease and discusses promising new therapies that are in development. PMID: 28561711 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - June 1, 2017 Category: Cancer & Oncology Authors: Hurvitz SA, Gelmon KA, Tolaney SM Tags: Am Soc Clin Oncol Educ Book Source Type: research

Novel Targeted Agents and Immunotherapy in Breast Cancer.
Abstract The treatment of breast cancer is generally determined according to breast cancer subtype: hormone receptor-positive (luminal), triple-negative (basal-like), and HER2-overexpressing breast cancer. Recent years have seen the development of exciting novel and potent therapeutics based on molecular pathways, immune modulation, and antibody conjugates. In this article, we cover new and emerging therapeutic areas and ongoing clinical trials that may result in further improvements in breast cancer outcomes. PMID: 28561712 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - June 1, 2017 Category: Cancer & Oncology Authors: Mayer IA, Dent R, Tan T, Savas P, Loi S Tags: Am Soc Clin Oncol Educ Book Source Type: research

Breast Cancer After Childhood, Adolescent, and Young Adult Cancer: It's Not Just About Chest Radiation.
Abstract Women who have been treated for a childhood, adolescent, or young adult cancer are at an increased risk for developing breast cancer at a young age, and breast cancer accounts for the most common subsequent malignant neoplasm among female childhood and adolescent cancer survivors. Risk of breast cancer in these survivors appears to be a multifaceted relationship between constitutional factors, exposures to radiation therapy (RT) and chemotherapy, and genetic predisposition. Given the significant morbidities and mortality associated with a breast cancer diagnosis, it is imperative that health care provider...
Source: Clinical Genitourinary Cancer - June 1, 2017 Category: Cancer & Oncology Authors: Hodgson D, van Leeuwen F, Ng A, Morton L, Henderson TO Tags: Am Soc Clin Oncol Educ Book Source Type: research

Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment.
Abstract Cancer survivorship care and research has typically focused on the health care needs of people with cancer following the acute phase of treatment. Work in this area, however, has faced challenges in identifying when treatment is complete for many forms of cancer. Acknowledging this challenge, the scope of survivorship research is often expanded to include patients also receiving maintenance or prophylactic therapy. Inherent in this expanded definition is the recognition that for many individuals, cancer is a chronic disease requiring extended treatment over many years. Three distinct patient populations c...
Source: Clinical Genitourinary Cancer - June 1, 2017 Category: Cancer & Oncology Authors: Jacobsen PB, Nipp RD, Ganz PA Tags: Am Soc Clin Oncol Educ Book Source Type: research

Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment.
Abstract Clinical trials and meta-analyses investigating bisphosphonates as an adjuvant breast cancer therapy have shown a consistent trend, with postmenopausal women and women receiving ovarian suppression with gonadotropin-releasing hormone therapy gaining improved breast cancer outcomes with the use of adjuvant bisphosphonate therapy. The interpretation of these data is controversial, because the primary endpoints of the majority of adjuvant bisphosphonate studies have been negative. Pros and cons as well as the value of adjuvant bisphosphonate therapy are discussed here. PMID: 28561722 [PubMed - in proces...
Source: Clinical Genitourinary Cancer - June 1, 2017 Category: Cancer & Oncology Authors: Gnant M, Van Poznak C, Schnipper L Tags: Am Soc Clin Oncol Educ Book Source Type: research

Conclusion Based on Insufficient Data in Study of Protein Intake Association With Breast Cancer Survival.
PMID: 28549231 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - May 28, 2017 Category: Cancer & Oncology Authors: Beale DJ Tags: J Clin Oncol Source Type: research

Transgender Patient Screening: Breast Cancer Risk Assessment and Screening Recommendations 
.
Transgender Patient Screening: Breast Cancer Risk Assessment and Screening Recommendations
. Clin J Oncol Nurs. 2017 Jun 01;21(3):E67-E70 Authors: Kiely D Abstract BACKGROUND: When a discrepancy exists between an individual's biologic sex and the deeply felt sense of being male or female, a transgender orientation may result. 
. OBJECTIVES: The purpose of this article is to summarize breast cancer risk assessment and screening recommendations for transgender individuals. 
. METHODS: A review of the literature was done to determine if evidence-based screening guidelines exist for transg...
Source: Clinical Genitourinary Cancer - May 20, 2017 Category: Cancer & Oncology Authors: Kiely D Tags: Clin J Oncol Nurs Source Type: research

Health Literacy Assessment: Feasibility in a Breast Surgical Oncology Clinic 
.
Health Literacy Assessment: Feasibility in a Breast Surgical Oncology Clinic
. Clin J Oncol Nurs. 2017 Jun 01;21(3):384-386 Authors: Keim-Malpass J, Doede A, Kennedy C, Showalter SL Abstract Health literacy is recognized as an integral component of high-quality health care. However, health literacy has been understudied in the context of cancer care delivery and surgical decision making. The goal of this article is to outline a process for implementation of a health literacy screening assessment within the routine practices of an academic breast surgical oncology clinic. The self-reported health lit...
Source: Clinical Genitourinary Cancer - May 20, 2017 Category: Cancer & Oncology Authors: Keim-Malpass J, Doede A, Kennedy C, Showalter SL Tags: Clin J Oncol Nurs Source Type: research

Oral Care: Exploring Education, Attitudes, and Behaviors Among Nurses Caring for Patients With Breast Cancer 
.
Oral Care: Exploring Education, Attitudes, and Behaviors Among Nurses Caring for Patients With Breast Cancer
. Clin J Oncol Nurs. 2017 Jun 01;21(3):371-378 Authors: Suminski JA, Inglehart M, Munz SM, Van Poznak CH, Taichman LS Abstract BACKGROUND: Patients treated for breast cancer often experience severe oral complications, such as mucositis, xerostomia, and infections, which can result in dose reductions and treatment delays, affecting treatment outcomes.
. OBJECTIVES: The purpose of this article is to explore oncology nurses' perceptions of their educational experiences, professional attit...
Source: Clinical Genitourinary Cancer - May 20, 2017 Category: Cancer & Oncology Authors: Suminski JA, Inglehart M, Munz SM, Van Poznak CH, Taichman LS Tags: Clin J Oncol Nurs Source Type: research

Cancer Recognition and Screening for Common Breast Disorders and Malignancy.
Abstract Breast cancer is predicted to be the most common newly diagnosed cancer in women in 2016. Screening mammography is the most commonly used method for the detection of breast cancer in women of average risk. A genetic risk assessment is recommended for women with a greater than 20% to 25% chance of having a predisposition to breast and ovarian cancer. Evaluation of a breast mass begins with a detailed history, assessment for cancer risk, and physical examination. PMID: 28499535 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - May 15, 2017 Category: Cancer & Oncology Authors: Bohon C Tags: Obstet Gynecol Clin North Am Source Type: research

Clinical Implications for Germline PTEN Spectrum Disorders.
Abstract Patients with PTEN hamartoma tumor syndrome (PHTS) may present to a variety of different subspecialties with benign and malignant clinical features. They have increased lifetime risks of breast, endometrial, thyroid, renal, and colon cancers, as well as neurodevelopmental disorders such as autism spectrum disorder. Patients and affected family members can be offered gene-directed surveillance and management. Patients who are unaffected can be spared unnecessary investigations. With longitudinal follow-up, we are likely to identify other non-cancer manifestations associated with PHTS such as metabolic, imm...
Source: Clinical Genitourinary Cancer - May 10, 2017 Category: Cancer & Oncology Authors: Ngeow J, Sesock K, Eng C Tags: Endocrinol Metab Clin North Am Source Type: research

Radiation Pneumonitis.
Abstract Radiation-induced lung injury is a well-known complication of thoracic radiation for patients with breast, lung, thymic, and esophageal malignancies, and mediastinal lymphomas. Improvements in radiation technique, as well as the understanding of the pathophysiology of radiation injury, have led to lower rates of pneumonitis and improved symptom control. Here, the authors provide an overview of the pathophysiology, diagnosis, and management of patients with radiation pneumonitis as a complication of treatment of chest malignancies. PMID: 28477633 [PubMed - in process] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - May 10, 2017 Category: Cancer & Oncology Authors: Bledsoe TJ, Nath SK, Decker RH Tags: Clin Chest Med Source Type: research

Understanding breast cancer - The long and winding road.
CONCLUSIONS: Breast cancer remains a serious public health issue worldwide. However, appreciable growth in our understanding of breast cancer in the past century has led to remarkable progress in the early detection, treatment and prevention of the disease. The clinical focus is shifting more towards tailored therapy as more targets are characterized and novel highly innovative approaches are developed. GENERAL SIGNIFICANCE: Tracing the history of breast cancer, highlights how increased awareness of the disease, and progress in research and development have enhance our understanding of the disease. PMID: 28194329...
Source: Clinical Genitourinary Cancer - February 16, 2017 Category: Cancer & Oncology Authors: Lukong KE Tags: BBA Clin Source Type: research